Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
OBJECTIVE
A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC).


METHODS
Consecutive patients with mCRC treated at the Military Medical Institute, Warsaw, between January 2003 and June 2008 were eligible. A total of 123 patients were identified (FOLFIRI, n = 67; capecitabine, n = 56).


RESULTS
The overall response rate with FOLFIRI was 28.1 versus 16.4% with capecitabine (P = 0.1398). Median time to disease progression with FOLFIRI was 8.8 versus 7.5 months with capecitabine (P = 0.20), and median overall survival was 19.0 versus 15.4 months (P = 0.93). In the FOLFIRI group, neutropenia and anaemia were significantly more frequent than in the capecitabine group. The main non-haematological toxicity was hand-foot syndrome found only in the capecitabine group.


CONCLUSIONS
Single-agent capecitabine and FOLFIRI are effective first-line regimens in patients aged > or =65 years with mCRC.
Stec
Rafał
R
Department of Oncology, Military Institute of the Health Services in Warsaw, Szaserów 128 Str., 00-909, Warsaw, Poland, drrafals@wp.pl.
Bodnar
Lubomir
L
Szczylik
Cezary
C
D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000740:Anemia / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D016017:Odds Ratio; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
Clin Colorectal Cancer. 2005 Nov;5(4):279-82
16356306
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
Jpn J Clin Oncol. 2007 Sep;37(9):686-91
17720736
Ann Ital Chir. 1998 Jul-Aug;69(4):491-6; discussion 496-7
9835125
Ann Oncol. 2002 Apr;13(4):566-75
12056707
Gastroenterol Clin North Am. 1993 Sep;22(3):517-33
8406728
N Engl J Med. 2000 Sep 28;343(13):905-14
11006366
J Clin Oncol. 2008 Mar 20;26(9):1443-51
18349394
J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5
15467030
J Clin Oncol. 2001 Nov 1;19(21):4097-106
11689577
Cancer. 2009 Jun 15;115(12):2617-29
19382200
J Clin Oncol. 2004 Apr 1;22(7):1209-14
15051767
Clin Cancer Res. 2008 Apr 1;14(7):2082-7
18381948
Cancer Control. 2000 Nov-Dec;7(6):548-56
11088063
J Clin Oncol. 2005 May 1;23(13):3104-11
15860870
J Clin Oncol. 2001 Apr 15;19(8):2282-92
11304782
World J Gastroenterol. 2006 Mar 28;12(12):1849-58
16609990